The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC).

Marshall R.  Posner

Honoraria - Naveris

Consulting or Advisory Role - Aveo; Calliditas Therapeutics; Galeria; Merck; Merus

Research Funding - BioNTech (Inst); Flamingo Pharma (Inst); Gilead Sciences (Inst); Hookipa Pharma (Inst); ISA Pharmaceuticals (Inst); Regeneron (Inst); Toragen (Inst)

Patents, Royalties, Other Intellectual Property - anti-Staphylococcal Monoclonal antibody (Inst); Uptodate editor

(OPTIONAL) Uncompensated Relationships - Frizent; Vivan Therapeutics

Deborah J.L.  Wong

Consulting or Advisory Role - Merck; Regeneron

Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); Flamingo Pharma (Inst); FSTAR (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Kura Oncology (Inst); Lilly; Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst); TopAlliance BioSciences Inc (Inst)

Kevin Joseph  Harrington

Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Codiak Biosciences (Inst); Inzen Therapeutics (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Scenic Biotech

Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Replimune (Inst)

Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)

Richard Lee  O'Neal

No Relationships to Disclose

Lukas  Makris

Employment - Stathmi

Stock and Other Ownership Interests  - Atrin Pharmaceuticals (I); Cerus (I); Immunomic Therapeutics (I); Opsidio (I); Sana Biotechnology (I)

Consulting or Advisory Role - Multiple Biotechnology companies

Morgane  Perdomini

Employment - Dynacure; Flamingo Therapeutics

Stock and Other Ownership Interests  - Flamingo Therapeutics

Susan  MacIntyre

Employment - Daiichi Sankyo (I); Flamingo Therapeutics

Research Funding - Flamingo Therapeutics

Andrew  Denker

Employment - ElevateBio Technologies; Flamingo Therapeutics

Leadership - Flamingo Therapeutics

Stock and Other Ownership Interests  - AlloVir; AstraZeneca; ElevateBo LLC; Flamingo Therapeutics; Merck

Nabil F.  Saba

Honoraria - American Journal OF Managed Care; AstraZeneca; Coherus Biosciences; Eisai; EMD Serono; Exelixis; Fulgent Pharma; GlaxoSmithKline; Inovio Pharmaceuticals; Merck; Novartis; Taiho Pharmaceutical; TOSK; vaccinex

Consulting or Advisory Role - Akeso Biopharma; Fulgent Pharma; GlaxoSmithKline; Seagen

Research Funding - Bristol-Myers Squibb; Exelixis

Patents, Royalties, Other Intellectual Property - Springer textbook Royalty; Uptodate chapter writing and editing

Travel, Accommodations, Expenses - Merck